These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 25090173)

  • 21. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service.
    Nordeck CD; Welsh C; Schwartz RP; Mitchell SG; O'Grady KE; Gryczynski J
    Drug Alcohol Depend Rep; 2022 Mar; 2():100031. PubMed ID: 36845893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.
    Melnick ER; Nath B; Dziura JD; Casey MF; Jeffery MM; Paek H; Soares WE; Hoppe JA; Rajeevan H; Li F; Skains RM; Walter LA; Patel MD; Chari SV; Platts-Mills TF; Hess EP; D'Onofrio G
    BMJ; 2022 Jun; 377():e069271. PubMed ID: 35760423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials.
    Bergen AW; Baurley JW; Ervin CM; McMahan CS; Bible J; Stafford RS; Mudumbai SC; Saxon AJ
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409790
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.
    Priest KC; Lovejoy TI; Englander H; Shull S; McCarty D
    J Gen Intern Med; 2020 Aug; 35(8):2365-2374. PubMed ID: 32291723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
    Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
    JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake of slow-release oral morphine as opioid agonist treatment among hospitalised patients with opioid use disorder.
    Brothers TD; Fraser J; MacAdam E; Morgan B; Webster D
    Drug Alcohol Rev; 2022 Feb; 41(2):430-434. PubMed ID: 34347327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The complex relation between access to opioid agonist therapy and diversion of opioid medications: a case example of large-scale misuse of buprenorphine in the Czech Republic.
    Mravčík V; Janíková B; Drbohlavová B; Popov P; Pirona A
    Harm Reduct J; 2018 Dec; 15(1):60. PubMed ID: 30514306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
    Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
    Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine.
    Fiellin DA; Barry DT; Sullivan LE; Cutter CJ; Moore BA; O'Connor PG; Schottenfeld RS
    Am J Med; 2013 Jan; 126(1):74.e11-7. PubMed ID: 23260506
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buprenorphine unobserved "home" induction: a survey of Ontario's addiction physicians.
    Srivastava A; Kahan M; Leece P; McAndrew A
    Addict Sci Clin Pract; 2019 May; 14(1):18. PubMed ID: 31039821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spontaneous reductions in smoking during double-blind buprenorphine detoxification.
    Patrick ME; Dunn KE; Badger GJ; Heil SH; Higgins ST; Sigmon SC
    Addict Behav; 2014 Sep; 39(9):1353-6. PubMed ID: 24845165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nurse Care Management for Opioid Use Disorder Treatment: The PROUD Cluster Randomized Clinical Trial.
    Wartko PD; Bobb JF; Boudreau DM; Matthews AG; McCormack J; Lee AK; Qiu H; Yu O; Hyun N; Idu AE; Campbell CI; Saxon AJ; Liu DS; Altschuler A; Samet JH; Labelle CT; Zare-Mehrjerdi M; Stotts AL; Braciszewski JM; Murphy MT; Dryden D; Arnsten JH; Cunningham CO; Horigian VE; Szapocznik J; Glass JE; Caldeiro RM; Phillips RC; Shea M; Bart G; Schwartz RP; McNeely J; Liebschutz JM; Tsui JI; Merrill JO; Lapham GT; Addis M; Bradley KA; ; Ghiroli MM; Hamilton LK; Hu Y; LaHue JS; Loree AM; Murphy SM; Northrup TF; Shmueli-Blumberg D; Silva AJ; Weinstein ZM; Wong MT; Burganowski RP
    JAMA Intern Med; 2023 Dec; 183(12):1343-1354. PubMed ID: 37902748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, double-blind evaluation of buprenorphine taper duration in primary prescription opioid abusers.
    Sigmon SC; Dunn KE; Saulsgiver K; Patrick ME; Badger GJ; Heil SH; Brooklyn JR; Higgins ST
    JAMA Psychiatry; 2013 Dec; 70(12):1347-54. PubMed ID: 24153411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.